Co-delivery of novel synthetic TLR4 and TLR7/8 ligands adsorbed to aluminum salts promotes Th1-mediated immunity against poorly immunogenic SARS-CoV-2 RBD
Inimmune to Present on Our Novel Cancer Immunotherapy INI-4001
Inimmune to present on their Novel Cancer Immunotherapy INI-4001 at the Medinvest Oncology Conference on December 6th, 2023
MISSOULA, MT, December 1, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel cancer immunotherapies and vaccine adjuvants and delivery systems, announced today that its Chief Operating Officer, Dr. David Burkhart, will give a presentation at the upcoming MedInvest Oncology Conference in Palo Alto California December 5-6th. The event brings […]
